APP carboxyl-terminal fragment without or with abeta domain equally induces cytotoxicity in differentiated PC12 cells and cortical neurons.
Mutations in the beta-amyloid precursor protein (APP) gene cause familial Alzheimer's disease (AD). Although amyloid beta peptide (Abeta) is the principal constituent of senile plaques in AD, other cleavage products of APP are also implicated in playing a role in the pathogenesis of AD. C-terminal fragments of APP (APP-CTs), that contain complete Abeta sequence, are found in neuritic plaques, neurofibrillary tangles and the cytosol of lymphoblastoid cells obtained from AD patients. Our previous report demonstrated that APP-CT105 causes death of differentiated PC12 cells and cultured rat cortical neurons (Kim and Suh [1996] J. Neurochem. 67:1172-1182) and induces strong inward currents in Xenopus oocyte (Fraser et al., [1996] J. Neurochem. 66:2034-2040). In the present study, to investigate which domain of APP-CT105 is responsible for the neurotoxicity, we have made deletion mutants of APP-CT105 without Abeta and transmembrane domain (TM) or without NPTY domain, a putative endocytosis signaling sequence, using the PCR-amplified strategy and the recombinant GST-fusion protein strategy. The effect on cell survival of the deletion mutants of APP-CT105 (8 microM) was then determined by the LDH and MTT assay. We found that C-terminal fragment without NPTY significantly causes cell death in NGF-differentiated PC12 cells and cultured rat cortical neurons. This finding suggests that NPTY may not play an important role in APP-CT105 mediated neurotoxicity. We found, however, that C-terminal fragment without Abeta and TM significantly induces neuronal cell death. Our results suggest that in addition to Abeta, C-terminal fragment of APP without Abeta and TM domain itself may also participate in the neuronal degeneration in AD.
Lee
J P
JP
Department of Pharmacology, College of Medicine and Neuroscience Research Institute, MRC, Seoul National University and Biomedical Brain Research Center, NIH, Seoul, Korea.
Chang
K A
KA
Kim
H S
HS
Kim
S S
SS
Jeong
S J
SJ
Suh
Y H
YH
D016564:Amyloid beta-Protein Precursor / Q000235:genetics* / Q000302:isolation & purification / Q000633:toxicity*; D000818:Animals; D016923:Cell Death / Q000187:drug effects; D002454:Cell Differentiation; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D004396:Coloring Agents / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D016297:Mutagenesis, Site-Directed; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D016716:PC12 Cells; D010446:Peptide Fragments / Q000235:genetics / Q000302:isolation & purification / Q000633:toxicity*; D017434:Protein Structure, Tertiary / Q000235:genetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013778:Tetrazolium Salts / Q000493:pharmacokinetics; D013844:Thiazoles / Q000493:pharmacokinetics
D016564:Amyloid beta-Protein Precursor; D004396:Coloring Agents; D010446:Peptide Fragments; D013778:Tetrazolium Salts; D013844:Thiazoles; C409682:amyloid beta-protein precursor CT105; D007770:L-Lactate Dehydrogenase; C022616:thiazolyl blue